Connor, Clark & Lunn Investment Management (CC&L)’s Lineage Cell Therapeutics LCTX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-26,393
| Closed | -$11.9K | – | 1604 |
|
|
2025
Q1 | $11.9K | Sell |
26,393
-159,515
| -86% | -$72K | ﹤0.01% | 1381 |
|
|
2024
Q4 | $93.4K | Sell |
185,908
-5,528
| -3% | -$2.78K | ﹤0.01% | 1363 |
|
|
2024
Q3 | $173K | Sell |
191,436
-16,328
| -8% | -$14.8K | ﹤0.01% | 1337 |
|
|
2024
Q2 | $207K | Buy |
207,764
+1,521
| +0.7% | +$1.52K | ﹤0.01% | 1258 |
|
|
2024
Q1 | $305K | Buy |
206,243
+43,560
| +27% | +$64.5K | ﹤0.01% | 1258 |
|
|
2023
Q4 | $177K | Sell |
162,683
-19,878
| -11% | -$21.7K | ﹤0.01% | 1278 |
|
|
2023
Q3 | $215K | Sell |
182,561
-70,714
| -28% | -$83.4K | ﹤0.01% | 1226 |
|
|
2023
Q2 | $357K | Buy |
253,275
+12,253
| +5% | +$17.3K | ﹤0.01% | 1075 |
|
|
2023
Q1 | $362K | Sell |
241,022
-20,880
| -8% | -$31.3K | ﹤0.01% | 969 |
|
|
2022
Q4 | $306K | Sell |
261,902
-26,397
| -9% | -$30.9K | ﹤0.01% | 974 |
|
|
2022
Q3 | $326K | Buy |
288,299
+152,971
| +113% | +$173K | ﹤0.01% | 902 |
|
|
2022
Q2 | $214K | Buy |
135,328
+123,328
| +1,028% | +$195K | ﹤0.01% | 920 |
|
|
2022
Q1 | $18K | Buy |
+12,000
| New | +$18K | ﹤0.01% | 1010 |
|
|
2020
Q4 | – | Sell |
-14,601
| Closed | -$14K | – | 980 |
|
|
2020
Q3 | $14K | Sell |
14,601
-41,940
| -74% | -$40.2K | ﹤0.01% | 907 |
|
|
2020
Q2 | $49K | Buy |
56,541
+5,823
| +11% | +$5.05K | ﹤0.01% | 984 |
|
|
2020
Q1 | $42K | Buy |
50,718
+28,568
| +129% | +$23.7K | ﹤0.01% | 971 |
|
|
2019
Q4 | $20K | Buy |
+22,150
| New | +$20K | ﹤0.01% | 906 |
|
|
2019
Q2 | – | Sell |
-14,000
| Closed | -$18K | – | 1037 |
|
|
2019
Q1 | $18K | Buy |
+14,000
| New | +$18K | ﹤0.01% | 890 |
|
|
2018
Q1 | – | Sell |
-111,510
| Closed | -$210K | – | 761 |
|
|
2017
Q4 | $210K | Sell |
111,510
-12,677
| -10% | -$23.9K | ﹤0.01% | 719 |
|
|
2017
Q3 | $309K | Buy |
124,187
+9,601
| +8% | +$23.9K | ﹤0.01% | 704 |
|
|
2017
Q2 | $316K | Buy |
114,586
+92,326
| +415% | +$255K | ﹤0.01% | 674 |
|
|
2017
Q1 | $67K | Buy |
+22,260
| New | +$67K | ﹤0.01% | 867 |
|